ZUMA-7: Axi-Cel Provides Durable Benefits Versus Standard of Care in Aggressive B-Cell Lymphoma

By Ariel Jones - Last Updated: December 14, 2021

According to data from the ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) led to significant and clinically meaningful improvement in event-free survival (EFS) compared with second-line standard of care in patients with relapsed or refractory large B-cell lymphoma (LBCL). The findings were presented by Frederick L. Locke, MD, of Moffit Cancer Center in Tampa, Florida, as a plenary abstract at the 2021 American Society of Hematology Annual Meeting.

“The results of ZUMA-7 herald a paradigm shift in how we treat large B-cell lymphoma,” said Dr. Locke. The improvement in EFS “is remarkable and indicates that patients with lymphoma not responding to initial treatment or relapsing within 12 months should have the opportunity to get this therapy.”
At a median follow-up of 24.9 months, axi-cel significantly improved EFS (hazard ratio [HR] = 0.398; p < 0.0001), with a median EFS that was more than four times longer than EFS with standard-of-care chemoimmunotherapy (8.3 vs. 2.0 months). The 24-month EFS was more than twice as long (41% vs. 16%).
In addition to the improvements in EFS, overall response rates (ORR) and complete response rates (CRR) were significantly higher with axi-cel compared with standard of care. ORR was 83% with axi-cel compared with 50% with standard of care (odds ratio [OR] = 5.31; p < 0.0001). The CRR was more than twice as high with axi-cel (65% vs. 32%).
Median overall survival was evaluated as a preplanned interim analysis. Overall survival favored axi-cel, but it did not meet statistical significance (not reached vs. 35.1 months; HR = 0.730; p = 0.027). The researchers noted that, among patients assigned to the standard-of-care arm, 56% received commercially available or investigational CAR T-cell therapy off-protocol as a subsequent therapy.
The safety of axi-cel was manageable and consistent with third-line use, according to Dr. Locke. Most patients in both arms experienced treatment-emergent grade ?3 adverse events (AEs). In the axi-cel arm, grade ?3 cytokine release syndrome (CRS) occurred in 6% of patients, while grade ?3 neurologic events occurred in 21% of patients. No grade 5 CRS or neurological events occurred. “For both study arms, the rates and types of adverse events were consistent with expectations based on previous trials and real-world experience,” Dr. Locke noted.

Post Tags:ASH 2021 Lymphoma/DLBCL NewsASH Annual Meeting 2021